One of the main problems of atherosclerosis disease is that it is diagnosed too late. Primary prevention is currently based on the evaluation of modifiable risk factors according to standardized recommendations. There is a need to find new biomarkers for subclinical atherosclerosis, which are independent of traditional cardiovascular risk factors and scores. The CNIC, UAM and IIS-FDJ researchers have discovered a panel of proteins, which are accumulated in the atheroma plaques themselves even in the earliest stages of formation. Moreover, the plasma abundance levels of these proteins could be used to predict the presence of subclinical atherosclerosis.
Diagnosis/biotech companies are sought for a license agreement.
Scientific publication: https://pubmed.ncbi.nlm.nih.gov/35152150/
